Lord Abbett & CO. LLC Sells 22,151 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lord Abbett & CO. LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,081 shares of the biopharmaceutical company's stock after selling 22,151 shares during the quarter. Lord Abbett & CO. LLC owned 0.06% of Regeneron Pharmaceuticals worth $67,365,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 10 shares during the period. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. increased its holdings in Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Catalyst Financial Partners LLC boosted its position in Regeneron Pharmaceuticals by 3.8% during the 2nd quarter. Catalyst Financial Partners LLC now owns 326 shares of the biopharmaceutical company's stock worth $343,000 after buying an additional 12 shares during the period. Finally, Trust Co. of Vermont lifted its holdings in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock worth $165,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ REGN traded down $9.67 during midday trading on Friday, hitting $731.30. 696,989 shares of the company traded hands, compared to its average volume of 847,429. The stock has a 50-day moving average price of $849.77 and a 200 day moving average price of $1,004.02. The firm has a market cap of $80.36 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.19 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 12-month low of $728.68 and a 12-month high of $1,211.20.

Analyst Ratings Changes

A number of research firms have weighed in on REGN. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Cantor Fitzgerald reissued a "neutral" rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,099.90.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.